Arbutus Biopharma - ABUS Stock Forecast, Price & News

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Arbutus Biopharma Price Performance

Shares of NASDAQ:ABUS remained flat at $2.40 during mid-day trading on Thursday. The stock had a trading volume of 7,925 shares, compared to its average volume of 919,042. Arbutus Biopharma has a twelve month low of $1.93 and a twelve month high of $6.50. The stock has a market cap of $359.88 million, a P/E ratio of -3.98 and a beta of 2.24. The business's fifty day moving average price is $2.57 and its 200-day moving average price is $2.70.

Arbutus Biopharma (NASDAQ:ABUS - Get Rating) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03. Arbutus Biopharma had a negative net margin of 211.09% and a negative return on equity of 61.57%. During the same period in the prior year, the business posted ($0.23) EPS. As a group, analysts expect that Arbutus Biopharma will post -0.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, JMP Securities decreased their price objective on shares of Arbutus Biopharma from $10.00 to $9.00 and set a "market outperform" rating on the stock in a report on Tuesday, June 28th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $7.13.